Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction

Pharmacotherapy

Volumn 28, Issue 12, 2008, Pages 1461-1470

  Tisdale, James E ^a,b   Overholser, Brian R ^a,b   Sowinski, Kevin M ^a,b   Wroblewski, Heather A ^a   Amankwa, Kwadwo ^a   Borzak, Steven ^c   Kingery, Joanna R ^d   Coram, Rita ^b   Zipes, Douglas P ^b   Flockhart, David A ^b   Kovacs, Richard J ^b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^d INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Arrhythmias; Heart failure; Ibutilide; Pharmacokinetics

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IBUTILIDE; NITRIC ACID DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVERSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIVER BLOOD FLOW; MALE; MULTICENTER STUDY; QT PROLONGATION; RISK FACTOR; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

EID: 57149123741     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.12.1461     Document Type: Article

References (39)

1. Kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 1995;91:799-806.
2. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
3. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
4. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996;94:1613-21.
5. Abi-Mansour P, Carberry PA, McCowan RJ, et al. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J 1998;136:632-42.
6. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Circulation 2006;114:700-52.
7. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 1997;96:4298-306.
8. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 1998;31:1414-19.
9. VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999;100:369-75.
10. Gowda RM, Khan IA, Punukollu G, et al. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly. Am J Ther 2004;11:95-7.
11. Stambler BS, Beckman KJ, Kadish AH, et al. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function. Am J Cardiol 1997;80:458-63.
12. Pfizer, Inc. Corvert (ibutilide) prescribing information. New York, NY; 2006.
13. Foster RH, Wilde MI, Markham A. Ibutilide: a review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs 1997;54:312-30.
14. Howard PA. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999;33:38-47.
15. Myers JD, Hickam JB. An estimation of the hepatic blood flow and splanchnic oxygen consumption in heart failure. J Clin Invest 1948;27:620-7.
16. Stenson RE, Constantino RE, Harrison DC. Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 1971;43:205-11.
17. Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV. Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 1984;69:57-64.
18. Benowitz NL, Meister W. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1976;1:389-405.
19. D'Argenio DZ, Schumitzky A. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California, 1997.
20. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker;1982.
21. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499-508.
22. Zito RA, Reid PR. Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med 1978;298:1160-3.
23. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978;3:177-201.
24. Gasic S, Heinz G, Kleinbloesem C, Korn A. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man. Br J Clin Pharmacol 1989;27(suppl 2):S225-34.
25. Munger MA, Chance M, Nair R, et al. Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure. J Clin Pharmacol 1992;32:70-6.
26. Nikolaidis LA, Poornima I, Parikh P, Magovern M, Shen YT, Shannon RP. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol 2006;47:1871-81.
27. Näbauer M, Beuckelmann DJ, Erdmann E. Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:386-94.
28. Tomaselli GF, Beuckelmann DJ, Calkins HG, et al. Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation 1994;90:2534-9.
29. Kääb S, Dixon J, Duc J, et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998;98:1383-93.
30. Tomaselli GF, Marbán E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 1999;42:270-83.
31. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:379-85
32. Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell Mol Life Sci 1999;55:494-505.
33. Houser SR, Piacento V III, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000;32:1595-607.
34. Li HG, Jones DL, Yee R, Klein GJ. Electrophysiologic substrate associated with pacing-induced heart failure in dogs: potential value of programmed stimulation in predicting sudden death. J Am Coll Cardiol 1992;19:444-9.
35. Kääb S, Nuss HB, Chiamvimonvat N, et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78:262-73.
36. Fu G-S, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997;18:281-9.
37. Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmias and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997;30:576-84.
38. Ks blockade reduces dispersion of repolarization in heart failure. Heart Rhythm 2005;2:731-8.
39. Antzelevich C. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 2007;9(suppl 4):iv4-14.